Gina Columbus

Akash Patnaik, MD, discusses immunotherapy and personalized medicine tactics in the field of prostate cancer, as well as the work that needs to be done with existing targeted therapies and biomarker development.

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

Marcia S. Brose, MD, PhD, sheds light on the biomarker assessment of the DECISION trial and the overall developments with biomarker research in the field of differentiated thyroid cancer.

Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.

Antonio Palumbo, MD, discusses the practice-changing findings of the phase III CASTOR trial for relapsed/refractory patients and what questions remain with the 3-drug regimen.

Marcia S. Brose, MD, PhD, discusses the updated SELECT findings, how practitioners are treating patients with lenvatinib, how its use compares with sorafenib, and the challenges that still exist with both therapies for patients with thyroid cancer.

Suzanne L. Topalian, MD, discusses progress in PD-1/PD-L1 immunotherapies and the prospects for developing biomarkers to better identify patients who would benefit from the new agents.

Reinhard Georg Dummer, MD, shares the encouraging phase III findings from the NEMO trial and how it shakes up the treatment paradigm for patients with NRAS-mutated melanoma.

Richard Pazdur, MD, has been named the acting director of the FDA's newly created Oncology Center of Excellence, which is aimed to expedite the development of novel combination products and support an integrated approach to oncology research.

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.

Thomas E. Hutson, DO, PharmD, discusses how nivolumab, cabozantinib, and lenvatinib/everolimus have significantly impacted the management of patients with renal cell carcinoma and promising combination regimens on the horizon to propel the field forward.

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

Noah Federman, MD, discusses challenges with treating pediatric patients and adolescent and young adults with sarcomas and ongoing efforts to overcome these obstacles.

Brian A. Van Tine, MD, PhD, discusses ongoing research in sarcomas, as well as provides insight on the impact existing drugs are making on the treatment landscape and what community oncologists need to know about this ever-changing field.

Jonathan C. Trent, MD, PhD, discusses notable findings in sarcomas that emerged at the 2016 ASCO Annual Meeting, as well as what lies ahead for the field of sarcomas.

A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

Perry Kennedy, PhD, discusses the goals of the RAS Initiative.

Luca Gianni, MD, discusses the significance of the long-term NeoSphere trial results and how the regimen is already impacting the landscape of HER2-positive breast cancer.

Sunil Verma, MD, discusses the current landscape in HER2-positive breast cancer and his views on neoadjuvant treatment options.

Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.

George D. Demetri, MD, discusses current trends in sarcoma care, how the field of sarcoma has paved the way for other tumor types, and emerging therapeutic advances in the field.

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

David P. Carbone, MD, PhD, shares insight on the CheckMate-032 and KEYNOTE-028 trials and others that are exploring immunotherapy in patients with small cell lung cancer.

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.

Robert Pili, MD, discusses the results and significance of an early-phase trial looking at the combination of entinostat and interleuken-2 and how it could shake up the treatment paradigm for renal cell carcinoma.

Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.

Sara Hurvitz, MD, discusses ongoing neoadjuvant studies in HER2-positive breast cancer, as well as what the future holds for neoadjuvant therapy.

Oliver Sartor, MD, discusses the combination regimens being explored with radium-223, its unique mechanism of action, and the associated risks and benefits.